Xeris Pharmaceuticals Inc. (XERS) Misses Q4 EPS by 3c

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q4 EPS of ($0.41), $0.03 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $7.09 million versus the consensus estimate of $8.21 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• Wall Street sees Muse as Meta’s next big catalyst after Connect event
• Paychex (PAYX) PT Lowered to $115 at UBS on Pace of Revenue Growth
• BlackBerry (BB) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance